Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares China Large-Cap ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while iShares China Large-Cap ETF trades at $33.51. Which is the better fit depends on your goals.
| AMPH | FXI | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $41.75 |
52-Week Low | $16.87 | $31.59 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
FXI trades at $33.48, up 0.21% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF shows mixed momentum with RSI_6 at 89.10 indicating overbought conditions. Recent news highlights China's push in AI and EVs, with a $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, potentially benefiting FXI's holdings. Support sits at $33, resistance at $34.
Outlook is cautiously optimistic due to China's tech and manufacturing rebound, though risks include U.S.-China tensions and valuation concerns. The ETF lacks current fundamental ratios, but sector growth offers upside if geopolitical and regulatory pressures ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
